Loading…
Also known as Cannabigerol
Non-psychoactive cannabinoid from which THC and CBD are enzymatically derived in the cannabis plant; early preclinical research suggests antibacterial, anti-inflammatory, and neuroprotective activity, though human trial data remain limited.
We link to relevant studies and leave interpretation to you and your healthcare professional.
Where people report using it and what trials suggest
Common claims the trials do not support
Cannabigerol — the 'mother cannabinoid'. Currently preclinical on nearly everything; consumer claims run years ahead of human data.
Safety notes: Presumed well-tolerated at low doses but no human safety data at scale; drug interactions unstudied.
Evidence grades reflect study quality and consistency, not marketing claims.
Ordered by strength of evidence, then result direction.
01The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo StudiesHenshaw FR, et al. · Cannabis and cannabinoid research · 2021PMID 33998900 ↗02The Use of Cannabinoids in Colitis: A Systematic Review and Meta-AnalysisCouch DG, et al. · Inflammatory bowel diseases · 2018PMID 29562280 ↗03Associated conditions and community-reported outcomes, wrapped together on one page. Aggregates appear only once enough reports arrive.
How this compound is sold in the UK, and where our readers typically find it.
Retailer search links — we may earn commission on purchases at no cost to you. Commission never affects our evidence ratings.
In the UK, CBD products fall under the FSA novel foods list — buy from retailers listing an FSA-assessed product.